🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Let’s play a little game. Let’s say that you’re the CSO at a cancer pharma company, and you have to choose a target to go after. Here’s a gene – high expression is associated with poor prognosis in brain cancer. Looks like a good candidate for an inhibitor right?

12 mahine 12 poster #Bonetumour Suspicion leads to early diagnosis which leads to early treatment and better survival Dr Manas Kalra Gargi Das Satya Prakash Yadav Shruti Kakkar Shweta Bansal Dr Neha Rastogi Dr.Rachit Khandelwal, MD Silky Jain

AACR 2025. Thank you scientific committee for considering such topics which have massive impact on improving access to high cost drugs. It was a moment of pride and honour for me to deliver a talk. ⁦⁦AACR⁩

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by U.S. FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe,

Salute Lance Naik Phogat. 🫡 But please correct the terminology for fallen soldiers who are Killed in Action.

Hmm…🤔 Now that’s interesting!

We are grateful to Ammunition Factory, Khadki, Pune: A Unit of Munitions India Limited (GOI) for supporting the treatment cost of Pediatric Cancer Patients for the year 2024/25. We were glad to welcome Mr. M.A. Khandare, Jt. General Manager, Mr. S.M. Kulkarni, Div Officer, GA,

🩸 22% grade 3/4 cytopenias ☠️ 1 toxic death (pneumonitis) 💉 Much lower than std 3mg/kg—excellent efficacy, acceptable toxicity in real-world setting. Promising Salvage treatment for Pediatric rrHL

The vast majority over discoveries are low hanging fruit when they are made. The key to scientific progress is progressively making more fruit low-hanging. One of the deep problems we have in science is that we reward the people who pick the fruit rather than the ones who lower

Out now, our bit for Low Dose ImmunoRx #LoDoNiv in relapse/refractory Ped Classic Hodgkin cHL #PHLDMG Tata Memorial Hospital Fixed #LoDoNiv 40mg + Benda -> 88%CR Will now be prospective multicenter INPHOG study PHO INDIA Excellent work Shyam Chetan Dhamne & rising star Aditya Narayan

This data will eventually pave the way for effective and accessible treatment for so many deserving children and families Heartiest Congratulations for this Gaurav Narula MD Aditya Narayan

📢 ACTREC-TMC invites Indian Nationals to apply for following Senior Resident & 1-yr TMC Fellowship tenured (non-permanent) posts 🗓️ Start: 01 Aug 2025 ⏳ Deadline: 31 May 2025, 17:00 IST 🔗 tinyurl.com/w2z32n9k

25 yrs in @IndianNavy & dived in my last year of service- 14 yrs later- 🤿s in Great Barrier Reef & Hawaii- today PADI certified Open Water diver! 🙏🙏 amazing crew Taj Coral Reef Resort & Spa Niyaz- best instructor ever! Reef here worth traveling all the way around the world! #LiveToDive

Aditya Narayan Shyam Gaurav Narula MD Chetan Dhamne Time is an essence, low dose immunotherapy must reach to the every corner of world and benefit the underprivileged ones ….make more noise Gaurav Narula MD

Aditya Narayan Shyam Gaurav Narula MD Chetan Dhamne It's great to se evidence of low-dose nivo in peds too👏🏾 Our group in Mexico has studied similar strategies in adult patients with encouraging results: doi.org/10.1007/s00277… ascopubs.org/doi/abs/10.120… Congrats to your team Dr. 💪🏾

The immunotherapeutic revolution in the treatment of B-cell hematologic malignancies has been a remarkable achievement in the annals of modern medicine. ow.ly/8XaT50VXkgq #clinicaltrialsandobservations

See you in a little while, we are very happy to welcome you. don't forget the 🔗 Registration: Please register at the following link: us06web.zoom.us/webinar/regist…

Challenges in managing and reporting adverse events in haematological malignancies in low-income and middle-income countries - The Lancet Haematology thelancet.com/journals/lanha…

A LMIC perspective on managing adverse events in haematological malignancy. Privileged to lead this The Lancet paper with authors from Argentina, Brazil, Zambia and Kenya. A wonderful experience. Tata Memorial Hospital thelancet.com/journals/lanha…

To be a clinical trialist (investigator- initiated > Pharma) is a long hard lonely journey of science, soul-searching, and serendipity! Do add the 5 years it takes to convince other investigators of your crazy idea !! 🤷🏻‍♂️